Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland
出版年份 2021 全文链接
标题
Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland
作者
关键词
-
出版物
BMC CANCER
Volume 21, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-01-05
DOI
10.1186/s12885-020-07710-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies
- (2019) NaNa Keum et al. Nature Reviews Gastroenterology & Hepatology
- Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013–2015
- (2019) Tracey S. E. Genus et al. BRITISH JOURNAL OF CANCER
- Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis
- (2018) Ruben Mujica-Mota et al. HEALTH TECHNOLOGY ASSESSMENT
- 1335TiPCOMPETE trial: Peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide vs. everolimus in progressive GEP-NET
- (2018) M E Pavel et al. ANNALS OF ONCOLOGY
- Gastroenteropancreatic Neuroendocrine Tumors
- (2018) Mauro Cives et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
- (2017) Jonathan Strosberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas
- (2017) Bryan Oronsky et al. NEOPLASIA
- Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
- (2017) Arvind Dasari et al. JAMA Oncology
- Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study
- (2016) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
- (2016) James C Yao et al. LANCET
- ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site
- (2016) M. Pavel et al. NEUROENDOCRINOLOGY
- A Tale of Two Thresholds: A Framework for Prioritization within the Cancer Drugs Fund
- (2016) Simon Leigh et al. VALUE IN HEALTH
- Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis
- (2014) S Ward et al. HEALTH TECHNOLOGY ASSESSMENT
- Elicitation of health state utilities in neuroendocrine tumours
- (2012) P. Swinburn et al. JOURNAL OF MEDICAL ECONOMICS
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of Somatostatins in Gastroenteropancreatic Neuroendocrine Tumor Development and Therapy
- (2010) Kjell E. Öberg et al. GASTROENTEROLOGY
- Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
- (2009) G Mickisch et al. BRITISH JOURNAL OF CANCER
- Health state utilities for non small cell lung cancer
- (2008) Beenish Nafees et al. Health and Quality of Life Outcomes
- Health state utility scores in advanced non-small cell lung cancer
- (2008) Scott Doyle et al. LUNG CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation